Asset Details
Do you wish to reserve the book?
Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras
Do you wish to request the book?
Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras
2019
Overview
The sporadic form of inclusion body myositis (IBM) is the most common late-onset myopathy. Its complex pathogenesis includes degenerative, inflammatory and mitochondrial aspects. However, which of those mechanisms are cause and which effect, as well as their interrelations, remain partly obscured to this day. In this review the nature of the mitochondrial dysregulation in IBM muscle is explored and comparison is made with other muscle disorders. Mitochondrial alterations in IBM are evidenced by histological and serum biomarkers. Muscular mitochondrial dynamics is disturbed, with deregulated organelle fusion leading to subsequent morphological alterations and muscle displays abnormal mitophagy. The tissue increases mitochondrial content in an attempt to compensate dysfunction, yet mitochondrial DNA (mtDNA) alterations and mild mtDNA depletion are also present. Oxidative phosphorylation defects have repeatedly been shown, most notably a reduction in complex IV activities and levels of mitokines and regulatory RNAs are perturbed. Based on the cumulating evidence of mitochondrial abnormality as a disease contributor, it is therefore warranted to regard IBM as a mitochondrial disease, offering a feasible therapeutic target to be developed for this yet untreatable condition.
Publisher
MDPI AG,MDPI
Subject
/ DNA, Mitochondrial - metabolism
/ Growth Differentiation Factor 15 - blood
/ Humans
/ Hypoglycemic Agents - therapeutic use
/ Kinases
/ Myopathy
/ Myositis
/ Myositis, Inclusion Body - drug therapy
/ Myositis, Inclusion Body - metabolism
/ Myositis, Inclusion Body - pathology
/ Patients
/ Pioglitazone - therapeutic use
/ Review
We currently cannot retrieve any items related to this title. Kindly check back at a later time.